Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer: A Multicenter, Randomized Controlled, Predictive Marker Clinical Trial

NCT00525200 is registered in ClinicalTrials.gov with Daniela Kandioler as lead sponsor.

NCT NCT00525200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00525200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer: A Multicenter, Randomized Controlled, Predictive Marker Clinical Trial
Lead sponsor
Daniela Kandioler
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2007
Completion date
December 31, 2012
Enrollment
170 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer